Okeiro

Okeiro is a Paris-based digital health company founded in 2019, focusing on precision medicine for transplant and chronic disease patients. Its core technology is a platform that integrates and analyzes patient data to provide predictive insights, notably through its iBox algorithm—an FDA and EMA-qualified biomarker for predicting long-term kidney graft survival. The company recently raised €10M in a Series A round (2025) to accelerate expansion, supporting its commercial rollout to healthcare professionals and its partnerships with life sciences companies for clinical research acceleration.

A precision medicine SaaS platform that integrates and analyzes multidimensional patient data for remote monitoring and predictive care. Its core is the FDA/EMA-qualified iBox predictive algorithm for graft survival, supplemented by clinical workflow tools (patient view, alerts, e-prescribing) and a research suite for real-world evidence and digital twin generation.

Okeiro competes in the crowded digital health monitoring space but is differentiated by its focus on complex chronic/transplant care and its regulatory-qualified predictive biomarker. In the clinical research sector, it competes with CROs and other endpoint specialists, with iBox's unique regulatory status providing a competitive edge in transplant trials.